25 March 2014
SIFI and NovaMedica sign agreement to market eight eye care products in Russia
March 25st, 2014
Moscow/Catania. - Leading Italian developer of innovative eye care solutions S.I.F.I. S.p.A. (SIFI) and Russian pharmaceutical company NovaMedica have entered into an exclusive commercial agreement for NovaMedica to market eight products developed and licensed by SIFI for the treatment of a wide range of ophthalmic pathologies in Russia and the CIS.
The products include prescription drugs to treat patients undergoing ocular interventions or suffering from infections or inflammatory diseases of the eye.
In particular, the portfolio includes two artificial tear formulations, EyestilTM and LacrisifiTM, developed to treat dry eye conditions resulting from altered or reduced tear production. Additionally, ColbiocinTM, NettaviscTM and NettacinTM offer three antibiotic options, available in multiple dosage forms, for the treatment of external eye infections. PrenacidTM is a water-soluble corticosteroid indicated for treatment of inflammations, including post-surgical inflammations, and allergies. OctiliaTM is an eye drop solution indicated for treatment of irritations, reddening, ocular congestion and pruritus due to allergic, chemical or physical causes. Lastly, Mirtilene ForteTM is a retinotrophic with a vasoprotective action helpful in cases of capillary fragility or vascular alterations due to diabetic retinopathy.
All the drugs have undergone clinical studies and are registered in Russia and the European Union. NovaMedica plans to initiate sales of some of these products in Russia later this year.
“Combined with other advanced pharmaceuticals already in NovaMedica’s pipeline, the SIFI products contribute to the creation of a balanced NovaMedica portfolio with drugs and therapies in place to meet the needs of both ophthalmologists and patients across a wide variety of ocular conditions,” said Fabrice Egros, NovaMedica COO. “This partnership enables us to quickly bring the latest therapies in the ophthalmology sector to Russian patients, a key element serving our short- and long-term strategy."
“We are pleased to strengthen our international distribution network through the agreement with NovaMedica,” stated Stefano Salvati, SIFI CEO. “Our cooperation leads to a wide-open and effective access to the rapidly growing ophthalmology market in Russia and other CIS countries. This agreement also offers an opportunity for further joint business activities and, undoubtedly, it will contribute to a broader availability of advanced ocular therapies to Russian patients".
NovaMedica is a Russian pharmaceutical company established in 2012 by DRI Holdings Limited, a portfolio company of Domain Associates LLC, and RUSNANO, which implements Russian government policy of fostering the development of hi-tech industries. The company’s strategy is aimed at localizing production of a wide range of new medicines and technologies in the Russian market, including screening and registration of new pharmaceuticals, and the creation of innovative GMP-standard manufacturing facilities.
For more details please visit www.novamedica.com
S.I.F.I. (Società Industria Farmaceutica Italiana) S.p.A. is an Italian pharmaceutical company operating in the ophthalmic sector since 1935 and the parent company of SIFI Group. SIFI Group companies develop, manufacture and market pharmaceutical products, diagnostic instruments and surgical equipment for the prevention and care of the most common ocular pathologies. EyestilTM, LacrisifiTM, ColbiocinTM, NettaviscTM, PrenacidTM, Mirtilene ForteTM are trademarks owned by SIFI S.p.A. TM
For more details please visit www.sifigroup.comPrint
22 February 2018
21 February 2018
21 February 2018
20 February 2018